drugset
drugset / Trial / NCT03412396

Apalutamide in Treating Patients With Prostate Cancer Before Radical Prostatectomy

NCT03412396 ↗

Phase 2 Active not recruiting 45 enrolled M.D. Anderson Cancer Center National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

This phase II trial studies how well apalutamide works in treating patients with prostate cancer before radical prostatectomy. Androgen can cause the growth of prostate cancer cells. Hormone therapy using apalutamide may fight prostate cancer by lowering the amount of androgen the body makes and may make it less likely for patients to receive radiation therapy after surgery.

Timeline

Start
2018-03-22
Primary completion
2024-10-03
Completion
2026-03-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Apalutamide Small molecule — Oral

Indications

prostate adenocarcinoma